This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Myovant Sciences Crescita futura

Criteri Future verificati 5/6

Informazioni chiave

59.0%

Tasso di crescita degli utili

60.27%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	23.4%
Tasso di crescita dei ricavi	27.6%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	10 Mar 2023

Aggiornamenti recenti sulla crescita futura

Recent updates

Myovant Sciences GAAP EPS of -$0.56 beats by $0.08, revenue of $100.23M misses by $2.13M

Jan 26

Myovant Sciences upgraded to outperform at SVB following additional Myfembree indication

Aug 09

Myovant stock gains ~6% after hours on Q1 revenue jump

Jul 27

Myovant Makes Commercial Progress As It Waits For FDA Decision On Myfembree

Jul 18

Analyst Forecasts For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher

Apr 28

Myovant: Poised To Overcome Regulatory Issues

Apr 26

Regulatory Setback Brings Myovant Sciences Stock To Attractive Levels

Apr 13

Myovant: Approved Drugs And Upcoming Catalysts Make This A Great Long-Term Play

Mar 26

Myovant: Catalysts Powering More Upside

Jan 02

Analysts Just Shipped A Substantial Upgrade To Their Myovant Sciences Ltd. (NYSE:MYOV) Estimates

May 14

New Forecasts: Here's What Analysts Think The Future Holds For Myovant Sciences Ltd. (NYSE:MYOV)

Feb 17

Earnings Update: Myovant Sciences Ltd. (NYSE:MYOV) Just Reported And Analysts Are Boosting Their Estimates

Feb 13

Analysts' Revenue Estimates For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher

Jan 12

Have Insiders Been Selling Myovant Sciences Ltd. (NYSE:MYOV) Shares This Year?

Dec 23

Myovant Sciences (NYSE:MYOV) Shareholders Have Enjoyed A 60% Share Price Gain

Nov 18

Previsioni di crescita degli utili e dei ricavi

NYSE:MYOV - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Utili	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
3/31/2025	618	-74	N/A	N/A	2
3/31/2024	555	-76	N/A	N/A	3
3/31/2023	418	-153	N/A	N/A	2
12/31/2022	379	-184	-271	-270	N/A
9/30/2022	333	-190	-260	-259	N/A
6/30/2022	306	-166	-232	-231	N/A
3/31/2022	231	-206	-270	-269	N/A
12/31/2021	198	-228	-263	-261	N/A
9/30/2021	145	-238	403	405	N/A
6/30/2021	67	-284	318	319	N/A
3/31/2021	59	-255	369	371	N/A
12/31/2020	35	-239	443	444	N/A
9/30/2020	33	-250	-198	-197	N/A
6/30/2020	33	-254	-217	-216	N/A
3/31/2020	N/A	-289	-222	-221	N/A
12/31/2019	N/A	-299	-256	-255	N/A
9/30/2019	N/A	-284	-252	-250	N/A
6/30/2019	N/A	-279	-247	-246	N/A
3/31/2019	N/A	-274	-225	-224	N/A
12/31/2018	N/A	-247	-207	-206	N/A
9/30/2018	N/A	-218	-176	-175	N/A
6/30/2018	N/A	-182	-136	-135	N/A
3/31/2018	N/A	-143	-118	-117	N/A
12/31/2017	N/A	-117	-94	-93	N/A
9/30/2017	N/A	-83	-70	-69	N/A
6/30/2017	N/A	-88	-46	-45	N/A
3/31/2017	N/A	-83	-19	-18	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che MYOV diventerà redditizio nei prossimi 3 anni, il che è considerato una crescita più rapida del tasso di risparmio ( 2.1% ).

Guadagni vs Mercato: Si prevede che MYOV diventerà redditizia nei prossimi 3 anni, il che è considerato una crescita superiore alla media del mercato.

Guadagni ad alta crescita: Si prevede MYOV diventerà redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di MYOV ( 27.6% all'anno) crescerà più rapidamente del mercato US ( 10.5% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di MYOV ( 27.6% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di MYOV è previsto essere elevato tra 3 anni

Scoprire le aziende in crescita

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2023/03/12 17:33
Prezzo dell'azione a fine giornata	2023/03/09 00:00
Utili	2022/12/31
Utili annuali	2022/03/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Myovant Sciences Ltd. è coperta da 8 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Brian Skorney	Baird
Mohit Bansal	Citigroup Inc
Jason Butler	Citizens JMP Securities, LLC

This company has been acquired

Myovant Sciences Crescita futura

Criteri Future verificati 5/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target increased to US$20.40

Consensus EPS estimates fall by 29%

Consensus EPS estimates fall by 31%

No longer forecast to breakeven

Consensus forecasts updated

Price target decreased to US$22.80

Recent updates

Myovant Sciences GAAP EPS of -$0.56 beats by $0.08, revenue of $100.23M misses by $2.13M

Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human Resources

Not The Buyout Offer That Myovant Shareholders Hoped For

Myovant Sciences Ltd. Appoints Shigeyuki Nishinaka as Director

Myovant May Delist from the New York Stock Exchange

Myovant Sciences rejects Sumitovant Biopharma's $22.75/share takeover offer

Principal Financial Officer recently sold US$174k worth of stock

Women Can Thank Pfizer And Myovant For MYFEMBREE

Myovant Sciences: Regulatory Overhang Cleared

General Counsel & Corporate Secretary recently sold US$569k worth of stock

Price target increased to US$20.40

Myovant Sciences upgraded to outperform at SVB following additional Myfembree indication

Myovant Sciences and Pfizer Inc. Receive U.S. FDA Approval of MYFEMBREE®, A Once-Daily Treatment for the Management of Moderate to Severe Pain Associated with Endometriosis

Myovant Sciences Ltd., Annual General Meeting, Oct 21, 2022

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Myovant stock gains ~6% after hours on Q1 revenue jump

CEO & Director recently sold US$144k worth of stock

Consensus EPS estimates fall by 29%

Myovant Makes Commercial Progress As It Waits For FDA Decision On Myfembree

Myovant Sciences and Pfizer Inc. Announce Results of the Phase 3 Spirit 1 and Spirit 2 Studies of Investigational Once-Daily Relugolix Combination Therapy

Myovant Sciences and Pfizer Inc. Announce FDA Acceptance of Supplemental New Drug Application for Myfembree

Consensus EPS estimates fall by 31%

No longer forecast to breakeven

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

Myovant Sciences Ltd. Announces European Commission Approval for Orgovyx (Relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer

Analyst Forecasts For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher

Price target decreased to US$22.80

Less than half of directors are independent

Myovant: Poised To Overcome Regulatory Issues

General Counsel & Corporate Secretary recently sold US$84k worth of stock

Regulatory Setback Brings Myovant Sciences Stock To Attractive Levels

Price target decreased to US$24.80

Myovant: Approved Drugs And Upcoming Catalysts Make This A Great Long-Term Play

Myovant Sciences Receives Positive CHMP Opinion for Orgovyx® (Relugolix) for the Treatment of Advanced Prostate Cancer

Forecast to breakeven in 2024

CEO & Director recently sold US$292k worth of stock

Myovant Sciences Ltd. Provides Revenue Guidance for the Three Months Ended December 31, 2021

General Counsel & Corporate Secretary recently sold US$73k worth of stock

Myovant: Catalysts Powering More Upside

Chief Medical Officer exercised options and sold US$62k worth of stock

Price target decreased to US$28.40

General Counsel & Corporate Secretary recently sold US$144k worth of stock

Chief Medical Officer exercised options and sold US$116k worth of stock

Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis

Price target decreased to US$33.25

Chief Medical Officer exercised options and sold US$342k worth of stock

Less than half of directors are independent

Key Executive recently sold US$70k worth of stock

Myovant Sciences and Pfizer Inc. Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids

Myovant Sciences Receives Positive CHMP Opinion for RYEQO® (Relugolix Combination Tablet) for the Treatment of Women With Uterine Fibroids

The U.S. Food and Drug Administration Informs Myovant Sciences Ltd. by Teleconference That They Have Placed A Partial Clinical Hold on the Phase 3 Serene Study (MVT-601-050)

Analysts Just Shipped A Substantial Upgrade To Their Myovant Sciences Ltd. (NYSE:MYOV) Estimates

Consensus forecasts updated

General Counsel & Corporate Secretary recently sold US$202k worth of stock

General Counsel & Corporate Secretary notifies of intention to sell stock

Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 Liberty Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids

Analysts update estimates

New Forecasts: Here's What Analysts Think The Future Holds For Myovant Sciences Ltd. (NYSE:MYOV)

Earnings Update: Myovant Sciences Ltd. (NYSE:MYOV) Just Reported And Analysts Are Boosting Their Estimates

Revenue and earnings miss expectations

Myovant Sciences and Pfizer Inc Announces Positive Data from Phase 3 SPIRIT Extension Study of Relugolix Combination Therapy in Women with Endometriosis

Analysts' Revenue Estimates For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher

Analysts increase revenue estimates to US$42.9m

Myovant Sciences Announces U.S. Availability of ORGOVYX™ for the Treatment of Advanced Prostate Cancer

Myovant Sciences Ltd Appoints David Marek as Principal Executive Officer and Member of the Board of Directors

Key Executive notifies of intention to sell stock

Myovant Sciences Ltd. and Pfizer Inc. Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women’S Health